Today's Veterinary Practice

JUL-AUG 2014

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link:

Contents of this Issue


Page 55 of 83

| ACVN NutritioN Notes 54 today's Veterinary Practice July/August 2014 table 4. recommended nutrient levels for diets (% dry Matter basis) a NUTRIENT RANGE FAT CHO PROTEIN N-3 FA b Healthy Dogs Low < 5 < 25 < 18 Nr c Moderate 10–15 25–54 18–22 Nr High > 15 > 55 > 22 Nr Healthy Cats Low < 9 < 24 <26 Nr Moderate 11–20 ≈ 30 27–30 Nr High > 20 > 40 > 30 Nr Canine Cancer Patients d % Dry matter basis 25–40 < 25 30–45 > 5 % Metabolizable energy 40–65 < 20 30-40 Feline Cancer Patients e % Dry matter basis 25–40 < 24 40–50 > 2 % Metabolizable energy 40–65 < 20 30–45 a. based on aaFCO minimum nutrient allowances for adult and growth life stages b. n-3 Fa = omega-3 fatty acids, including dha and ePa c. nr = values not reported in aaFCO; suggested n-6:n-3 ratio of 1:1–2.5:1 d. Canine values derived from reference 3 e. Feline values extrapolated from canine values; lower dietary fat based on concurrent disease states, such as pancreatitis, hyperlipidemia, and cholangitis. table 5. Commercial diet types appropriate for veterinary Cancer Patients a CATEGORY OF DIET CANINE APPROPRIATE FELINE APPROPRIATE Fish as primary protein source (otC b ) Yes Yes Grain-free (not calorie- reduced) Yes Yes Kitten No Yes Performance Yes No Puppy Yes No Recovery/critical care Yes Yes Hypoallergenic, diabetic (selected diets) Yes c Yes d a. these categories of commercial diets fall within the nutrient profiles recommended for veterinary cancer patients. b. OtC = over the counter c. royal Canin diabetic (canned) d. hill's Prescription diet d/d (canned) and m/d, iaMS Skin & Coat response lb, Purina dM, royal Canin hypoallergenic (canned) and diabetic (canned) Supplements: Appropriate for Veterinary Cancer Patients? Caregivers are often keen to provide im- mune-enhancing, health-boosting supple- ments to their pets diagnosed with cancer. limited evidence-based studies are avail- able to substantiate dosage, duration, tim- ing, or risk versus benefit; therefore, it is best to proceed with caution. some supplements have been docu- mented through clinical studies in the can- cer patient: Omega-3 fatty acids , which include ePA and DHA, are recommended in various formats: • omega-3 fatty acids = > 5% dry matter 3 • ratio of omega-6 to omega-3 (ePA/ DHA) = 1:1 to 2.5:1 3 • ePA/DHA = 450 mg/100 kcal of daily energy requirement (Der); calculated based on Hill's Prescription Diet n/d nutrient profile Antioxidants are contraindicated during ongoing chemotherapy or radiation ther- apy. • Although oxidant-induced cellular damage is significant following completion of treatment protocol, human studies have reported conflicting results regarding AoX supplementation. 16 • to date, no companion animal studies evaluating AoX supplementation have been reported. Glutamine (GlN) is a primary fuel for en- terocytes that can become depleted dur- ing prolonged anorexic–hyporexic states, especially with associated Gi stress. Many tumors exhibit high rates of GlN con- sumption. • GlN has been shown to improve: 17 » Protein balance in tumor-bearing animals » Natural killer cell function. • recommended supplementation following Gi surgery = 500 mg GlN/100 kcal Der 14 • No consensus on usefulness of GlN supplementation in nonsurgical cancer patients For further information on the use of nutritional supplements in veterinary medicine, read Surveying Supplements: Current Trends, Research, & Recommendations—in the May/June 2014 issue of Today's Veterinary Practice— at

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - JUL-AUG 2014